Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering
Rhea-AI Summary
Sunshine Biopharma (NASDAQ:SBFM) priced a reasonable best efforts public offering expected to raise approximately $6.0 million in gross proceeds. The offering includes 12,000,000 Common Units or Pre-Funded Units at $0.50 per Common Unit (or $0.49999 per Pre-Funded Unit).
Each unit consists of one share of common stock or one pre-funded warrant plus two Series C warrants with a $0.50 exercise price, exercisable immediately. Closing is expected around May 19, 2026. Net proceeds are earmarked for general corporate purposes and working capital. The SEC declared the Form S-1 registration statement effective on May 18, 2026.
Positive
- Gross proceeds of approximately $6.0 million to bolster liquidity
- Offering of 12,000,000 units fully registered under an effective Form S-1
- Immediate exercisability of Series C warrants could provide additional future capital
- Net proceeds allocated to general corporate purposes and working capital
Negative
- Potential shareholder dilution from 12,000,000 new shares and associated warrant exercises
- Two Series C warrants per unit create ongoing warrant overhang for up to five years
News Market Reaction – SBFM
In the May 18 session, SBFM gained 79.51%, reflecting a significant positive market reaction. Argus tracked a peak move of +383.0% during that session. Argus tracked a trough of -29.5% from its starting point during tracking. Our momentum scanner triggered 69 alerts that day, indicating high trading interest and price volatility. Trading volume was exceptionally heavy at 380.6x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 03 | Offering closing | Negative | -18.2% | Closed $2.46M registered direct offering with common and pre-funded warrants. |
| Apr 02 | Offering announcement | Negative | +8.2% | Announced $2.46M registered direct offering priced at the market under Nasdaq rules. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Past offerings produced mixed reactions but an average move of -5.02%, suggesting generally negative yet variable responses to dilution events.
Recent history shows Sunshine Biopharma repeatedly using equity offerings for funding. In April 2025, it announced and then closed a $2.46 million registered direct offering, involving common stock and pre-funded warrants, both under an effective registration statement and led by Aegis Capital. One announcement day saw a +8.17% move, while closing the deal saw a -18.22% move. Today’s best-efforts public offering for roughly $6.0 million continues this pattern of capital-raising via unit structures with warrants.
Key Terms
pre-funded warrant financial
series c warrants financial
registration statement on form s-1 regulatory
prospectus regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
FORT LAUDERDALE, FL / ACCESS Newswire / May 18, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and developing life‑saving medicines across oncology, antivirals, and other key therapeutic areas, today announced the pricing of a public offering made on a reasonable best efforts basis with gross proceeds to the Company expected to be approximately
The offering consisted of 12,000,000 Common Units (or Pre-Funded Units), each consisting of (i) one (1) share of Common Stock or one (1) Pre-Funded Warrant and (ii) two (2) Series C Warrants to purchase one (1) share of Common Stock per warrant at an initial exercise price of
The transaction is expected to close on or about May 19, 2026, subject to the satisfaction of customary closing conditions. The Company expects to use the net proceeds from the offering for general corporate purposes and working capital.
Aegis Capital Corp. is acting as the exclusive placement agent for the offering. Sichenzia Ross Ference Carmel LLP is acting as counsel to the Company. Kaufman & Canoles, P.C. is acting as counsel to Aegis Capital Corp.
A registration statement on Form S-1 (No. 333-295800) previously filed with the U.S. Securities and Exchange Commission (the "SEC") on May 12, 2026 was declared effective by the SEC on May 18, 2026. The offering is being made only by means of a prospectus. A final prospectus describing the terms of the offering will be filed with the SEC and will be available on the SEC's website located at www.sec.gov. Electronic copies of the final prospectus may be obtained, when available, by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at syndicate@aegiscap.com, or by telephone at +1 (212) 813-1010. Before investing in this offering, interested parties should read in their entirety the prospectus, which provides more information about the Company and such offering.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Sunshine Biopharma Inc.
Sunshine Biopharma currently markets 60 generic prescription drugs in Canada, with 12 additional launches planned for the remainder of 2026. The Company is also advancing two proprietary drug development programs:
K1.1 mRNA, an mRNA‑Lipid Nanoparticle therapeutic candidate targeting liver cancer.
PLpro protease inhibitor, a small‑molecule antiviral candidate for SARS‑related coronavirus infections.
Additional information is available at www.sunshinebiopharma.com.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company's product development and business prospects, the closing of the offering, and the use of proceeds from the offering, and can be identified by the use of words such as "may," "will," "expect," "project," "estimate," "anticipate," "plan," "believe," "potential," "should," "continue" or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans, including the risk factors described in the Company's documents filed with the Securities and Exchange Commission. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned as a result of these risks. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.
Camille Sebaaly, CFO
Direct Line: 514‑814‑0464
camille.sebaaly@sunshinebiopharma.com
SOURCE: Sunshine Biopharma Inc.
View the original press release on ACCESS Newswire